Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04418661
Other study ID # TCD16210
Secondary ID U1111-1244-2555T
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date June 9, 2020
Est. completion date April 4, 2024

Study information

Verified date April 2024
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary Objectives: - Part 1 - To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in participants with advanced solid tumors. - To define the MTD and RP2D for the combination of SAR442720 and pembrolizumab in participants with solid tumors. - Part 2 - To determine the anti-tumor activity of SAR442720 in combination with pembrolizumab. - Part 3A - To define the MTD and RP2D for the combination of SAR442720 and adagrasib in participants with KRAS G12C NSCLC - To characterize the safety and tolerability of SAR442720 in combination with adagrasib in participants with KRAS G12C NSCLC - Part 3B - To determine the anti-tumor activity of SAR442720 in combination with adagrasib in participants with KRAS G12C NSCLC - Part 4 - To evaluate the impact of food on the PK of SAR442720 when dosed with pembrolizumab. - To evaluate the impact of the formulations (formulation 1 and formulation 2) on the PK of SAR442720 when dosed with pembrolizumab. Secondary Objectives: - Part 1 - To assess the PK of SAR442720 with pembrolizumab, and the PK of pembrolizumab with SAR442720. - To estimate the anti-tumor effects of SAR442720 with pembrolizumab. - Part 2 - To assess the safety profile of SAR442720 combined with pembrolizumab. - To assess other indicators of anti-tumor activity. - To assess the PK of SAR442720 with pembrolizumab, and the PK of pembrolizumab with SAR442720. - Part 3A - To characterize the PK of SAR442720 with adagrasib, and the PK of adagrasib with SAR442720. - To estimate the anti-tumor effects of SAR442720 with adagrasib - Part 3B - To assess the safety profile of SAR442720 with adagrasib in participants with KRAS G12C NSCLC. - To assess other indicators of anti-tumor activity. - To assess the PK of SAR442720 with adagrasib, and the PK of adagrasib with SAR442720. - Part 4 - To assess the safety and tolerability of SAR442720 formulations with pembrolizumab - To estimate the anti-tumor effects of SAR442720 with pembrolizumab.


Description:

This open label Phase 1 multicenter study is designed to evaluate the safety and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SAR442720 in combination with pembrolizumab in participants with solid tumors in Part 1. In Part 2, in the expansion cohort (Cohort A) we will assess the antitumor activity and safety of SAR442720 combined with pembrolizumab in participants with metastatic 1L lung cancer. In Part 3, we will evaluate the safety, MTD, RP2D and antitumor activity of SAR442720 in combination with adagrasib in participants with lung cancer and KRAS G12C mutation. In Part 4, we will evaluate the impact of the formulations (formulation 1 and formulation 2) and of the food on the PK of SAR442720 when dosed in combination with pembrolizumab. The expected duration of study intervention for participants may vary, based on progression date; median expected duration of study per participant is estimated to be about 10 months in Part 1, Part 3 and Part 4 (up to 1 month for screening, a median of 6 months for treatment, and a median of 3 months for long term follow-up) and in Part 2 16 months (up to 1 month for screening, a median of 12 months for treatment and a median of 3 months for long term follow up.)


Recruitment information / eligibility

Status Terminated
Enrollment 65
Est. completion date April 4, 2024
Est. primary completion date April 4, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants must be = 18 years of age. - Histologically proven diagnosis of advanced solid tumors. - Participants must have one or more of the following molecular aberrations (Part 1): KRAS mutations and amplifications, BRAF Class 3 mutations, or NF1 LOF mutations. - Participants must have following molecular aberration (Part 3A and 3B): - KRAS G12C mutation. - At least 1 measurable disease per RECIST 1.1 criteria. - Eastern Cooperative Oncology Group (ECOG) performance status 0-1. - Woman of childbearing potential must agree to follow contraceptive guidance. - Capable of giving signed informed consent. Exclusion Criteria: - Predicted life expectancy <3 months. - Primary central nervous system (CNS) tumors. - Symptomatic or impending cord compression. Stable CNS disease is allowed. - History of cerebrovascular stroke or transient ischemic attack within previous 6 months. - Prior solid organ or hematologic transplant. - History or current retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vascular occlusion (RVO), neovascular macular degeneration. - Any clinically significant cardiac disease. - Active, known or suspected autoimmune disease. - History of or current interstitial lung disease or pneumonitis. - Receipt of a live-virus vaccination within 28 days, viral vaccine that do not contain live virus within 7 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted. - Known infection with human immunodeficiency virus (HIV), known uncontrolled hepatitis B infection, active tuberculosis, or severe infection requiring parenteral antibiotic treatment. - Inadequate hematologic, hepatic and renal function. - Known second malignancy. - Impairment of gastrointestinal function. - Any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol. - History of severe allergic reaction to any of the study intervention components. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SAR442720
Pharmaceutical form: Varies Route of administration: Varies
Pembrolizumab
Pharmaceutical form:Sterile Lyophilized powder for reconstitution Route of administration: Infusion
Adagrasib
Pharmaceutical form:Sterile Tablet Route of administration: Oral

Locations

Country Name City State
Argentina Investigational Site Number : 0320002 Buenos Aires
Argentina Investigational Site Number : 0320001 Caba Buenos Aires
Argentina Investigational Site Number : 0320004 Caba Ciudad De Buenos Aires
Argentina Investigational Site Number : 0320003 Rosario Santa Fe
Australia Investigational Site Number : 0360003 Heidelberg West Victoria
Australia Investigational Site Number : 0360002 Randwick New South Wales
Australia Investigational Site Number : 0360001 Woolloongabba Queensland
Chile Investigational Site Number : 1520001 Santiago Reg Metropolitana De Santiago
Chile Investigational Site Number : 1520002 Temuco
Chile Investigational Site Number : 1520003 Viña del Mar Valparaíso
Korea, Republic of Investigational Site Number : 4100003 Cheongju-si Chungcheongbuk-do
Korea, Republic of Investigational Site Number : 4100002 Seongnam-si, Gyeonggi-do
Korea, Republic of Investigational Site Number : 4100001 Seoul Seoul-teukbyeolsi
Netherlands Investigational Site Number : 5280001 Leiden
Spain Investigational Site Number : 7240001 Madrid / Madrid Madrid, Comunidad De
Spain Investigational Site Number : 7240002 Madrid / Madrid Madrid, Comunidad De
Spain Investigational Site Number : 7240003 Valencia / Valencia Valenciana, Comunidad
Taiwan Investigational Site Number : 1580002 Tainan
Taiwan Investigational Site Number : 1580001 Taipei
United States ~University of Texas - MD Anderson Cancer Center Site Number : 8400001 Houston Texas
United States University of California Irvine Medical Center Site Number : 8400002 Orange California

Sponsors (3)

Lead Sponsor Collaborator
Sanofi Mirati Therapeutics Inc., Revolution Medicines, Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Chile,  Korea, Republic of,  Netherlands,  Spain,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events (AEs) SAR442720 and pembrolizumab Part 1:
Incidence, nature, and severity of treatment emergent AEs and serious adverse events (SAEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 for the combination of SAR442720 and pembrolizumab.
21 days
Primary Incidence of study-drug related Dose Limiting Toxicities (DLTs) Part 1 and 3A:
Incidence of study drug-related dose-limiting toxicities (DLTs) in Cycle 1.
up to 2 years
Primary Objective Response Rate (ORR) Part 2 and 3B:
Objective response rate defined as the proportion of participants who have a confirmed CR or partial response (PR) determined by investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
up to 2 years
Primary Incidence of Adverse Events (AEs) SAR442720 and adagrasib Part 3A:
Incidence, nature, and severity of TEAEs and SAEs, graded according to NCI CTCAEv5.0 for the combination of SAR442720 and adagrasib.
up to 2 years
Primary Part 4: Plasma concentrations of SAR442720 in combination with pembrolizumab under impact of food up to 2 years
Secondary Part 1 and 2: Plasma concentrations of SAR442720 up to 2 years
Secondary Part 1 and 2: Serum concentration of pembrolizumab up to 2 years
Secondary Objective response rate (ORR) Part 1 and Part 4 Part 1 and Part 4:
Objective response rate of SAR442720 and pembrolizumab in all participants. ORR of combination therapy with SAR442720 and pembrolizumab will be based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.
up to 2 years
Secondary Duration of response (DoR) Part 1 and Part 2 and 3B:
Duration of response per RECIST v1.1 is defined as the interval from the first documentation of CR (complete response) or PR (partial response) to the earlier of the first documentation of definitive disease progression or death due to any cause, whichever occurs first.
up to 2 years
Secondary Incidence of Adverse Events Part 2 and 3B and Part 4:
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to the NCI CTCAE v5 for the combination of SAR442720 and pembrolizumab.
up to 2 years
Secondary Time to Response (TTR) Part 2 and 3B:
Time to response (TTR) defined as the time from the first administration of investigational medicinal product (IMP) to the first documented evidence of PR or CR determined by the Investigator per RECIST v1.1 (for NSCLC).
up to 2 years
Secondary Clinical Benefit Rate (CBR) Part 2 and 3B:
Clinical benefit rate (CBR) including confirmed CR or PR at any time or stable disease (SD) of at least 6 months (determined by the Investigator per RECIST v1.1.
up to 2 years
Secondary Disease Control Rate (DCR) Part 2 and 3B:
Disease control rate (DCR) including confirmed CR or PR or stable disease (SD) as determined by the Investigator per RECIST v1.1.
up to 2 years
Secondary Progression free survival (PFS) Part 2 and 3B:
Progression free survival (PFS), defined as the time from the date of first IMP administration to the date of the first documented disease progression determined by the Investigator as per RECIST v1.1 or death due to any cause, whichever occurs first.
up to 2 years
Secondary Part 3A: Plasma concentrations of SAR442720 up to 2 years
Secondary Part 3A: Plasma concentrations of adagrasib up to 2 years
Secondary Objective Response Rate (ORR) of SAR442720 and adagrasib Part 3A:
ORR of SAR442720 and adagrasib in all participants. ORR of combination therapy with SAR442720 and adagrasib will be based on RECIST v1.1.
up to 2 years
Secondary Duration of Response (DOR) of SAR442720 and adagrasib Part 3:
DOR of SAR442720 and adagrasib in all participants. ORR of combination therapy with SAR442720 and adagrasib will be based on RECIST v1.1.
up to 2 years
Secondary Part 3B: Plasma concentrations of SAR442720 and adagrasib up to 2 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02226289 - Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment Phase 2
Terminated NCT02566421 - Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery N/A
Completed NCT01606033 - Study of Stress and Life Quality of Patients Participating in Clinical Trials Versus Patients Non Participating N/A
Completed NCT00525057 - Dalteparin in Preventing DVT in Participants With Cancer N/A
Terminated NCT03871348 - A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors Phase 1
Completed NCT02775292 - Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 Phase 1
Recruiting NCT05617716 - Spine Radiosurgery for Symptomatic Metastatic Neoplasms Phase 2
Active, not recruiting NCT05103358 - Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) Phase 2
Recruiting NCT02560311 - Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis N/A
Completed NCT02492711 - Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Phase 3